Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 100.00%.
Reported quarterly gross margin; no daily interpolation.
Limited quarterly history available
Gross Margin needs at least three reported quarters before a meaningful chart is shown.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
N/A
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+142.69%
vs the sector median at left
Odyssey Therapeutics, Inc.
Market Cap
$870.81M
Gross Margin
100.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$857.16M
Gross Margin
44.60%
TTM Avg
46.45%
3Y Avg
50.53%
5Y Avg
59.76%
Market Cap
$884.97M
Gross Margin
99.98%
TTM Avg
98.71%
3Y Avg
99.36%
5Y Avg
-14.89%
Market Cap
$887.99M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$853.13M
Gross Margin
91.39%
TTM Avg
91.47%
3Y Avg
93.85%
5Y Avg
95.64%
Market Cap
$852.35M
Gross Margin
35.27%
TTM Avg
46.37%
3Y Avg
58.90%
5Y Avg
58.90%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $870.81M | 100.00% | N/A | N/A | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | 79.53% | 79.30% | 80.66% | 83.15% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | 44.60% | 46.45% | 50.53% | 59.76% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 99.98% | 98.71% | 99.36% | -14.89% |
| Alumis Inc. (ALMS)vs › | $855.38M | 88.23% | 42.73% | 21.36% | 21.36% |
| Bioventus Inc. (BVS)vs › | $887.50M | 68.00% | 67.52% | 65.94% | 67.78% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | 0.00% | 0.00% | 0.00% | 0.00% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 91.39% | 91.47% | 93.85% | 95.64% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | 35.27% | 46.37% | 58.90% | 58.90% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 35.97% | 27.94% | 30.11% | 34.47% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
